NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking...
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking...
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed...
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)...
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
BOSTON, Sept. 8, 2025 /PRNewswire/ -- At the 2025 World Artificial Intelligence Conference (WAIC) in August 2025, Gu demonstrated the...
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,...
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in...
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M...
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The...
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to...
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,...
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
This Isn’t Sci-Fi, it’s Spider Silk!DENVER, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to...